Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

CORT

Phase 2

Dazucorilant

Amyotrophic Lateral Sclerosis (ALS)

March 2025

DAZALS trial: 4/15/24- Enrollment complete. Results by Q4 2024. 12/11/24- Failed to meet Ph2 primary endpoint. OLE study will continue w/ OS data in March 2025.

Additional Data readout

CADL

Phase 2a

CAN-2409 + Valacyclovir w/ PD-(L)1 targeting agents

Non-small cell Lung Cancer (NSCLC)

Q1 2025

9/26/23- Positive Initial data. 4/25/24- Present topline overall survival data at ASCO '24 on June 3, 2024. 3/13/25- Biomarker & OS data in Q1 '25

Data readout

CMPX

Phase 2/3

CTX-009 (DLL4 and VEGF-A bispecific antibody)

BTC (Biliary tract cancer)

End of Q1 2025

COMPANION-002. 4/25/24- Granted Fast Track Designation. 8/6/24- Completes enrollment. 2/27/25- Report topline data by the end of Q1 2025.

Data readout

KROS

Phase 1

KER-065

Neuromuscular disease, Duchenne muscular dystrophy (DMD)

Q1 2025

Initiate trial in Q1 2024 and report data in Q1 '25

Data readout

GLUE

Phase 1

MRT-6160

Systemic and neurological autoimmune and inflammatory diseases

Q1 2025

6/14/24- Preclinical data at EULAR '24. 8/19/24- Initiated SAD/MAD studies. 10/28/24- License agreement w/$NVS. 1/10/25- Report initial SAD/MAD data in Q1 2025.

Data readout

CORT

Phase 3

Relacorilant + Nab-paclitaxel

Ovarian cancer

Q1 2025

Suspected mover in Q1 '25: ROSELLA Trial. 7/29/24 - Enrollment complete. 2/26/25- Report data in Q1 2025.

Data Readout

GLUE

Phase 1/2

MRT-2359

Metastatic NSCLC (MYC-driven tumors)

Q1 2025

6/27/24 - Favorable safety & PD profile in 0.5mg cohort. 12/5/24- Reported results from dose escalation arms. Recommended Ph2 dose determined as 0.5 mg. 1/10/25- Share updated data in Q1 2025.

Data readout

WVE

Phase 2

WVE-N531

DMD (Duchenne muscular dystrophy)

Q1 2025

FORWARD-53 trial. 12/15/23- Initiated dosing. 2/27/24- Present POC (Part A) data at MDA '24. 8/12/24- FDA RPD designation. 9/24/24- Reported 24-wk interim data. 3/4/25- 48wk data in Q1 2025.

Data Readout

PCVX

Phase 2

VAX-24

Invasive PneumococcaI Disease (IPD) in Infants

End of Q1 2025

3/4/24- Enrollment completed. 2/25/25- Topline safety, tolerability & immunogenicity data from 3-dose series by end of Q1 2025 & topline data from the booster dose by the end of 2025.

Data readout

SONN

Phase 1b/2a

SON-1010 (IL12-FHAB)

Solid tumors, Platinum-resistant ovarian cancer

Q1 2025

SB221 trial. 5/20/24- Updated clinical data. Dose escalation continues. 5/28/24- Present as Trial in Progress at ASCO '24 on 6/3/24. 12/9/24- Enrollment ongoing w/ data update in Q1 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20